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Purpose: Chronic obstructive pulmonary disease (COPD) is associated with altered metabolism 
and body composition that accompany poor outcomes. We aimed to determine whether metabolic 
derangements in COPD are associated with skeletal muscle deconditioning and/or physical 
inactivity, independent of pulmonary obstruction.  
Methods: We characterized serum metabolites associated with muscle oxidative capacity or 
physical activity in 44 COPD patients (FEV1=61±4%predicted) and 63 current and former 
smokers with normal spirometry (CON) (FEV1=93±2%predicted). Medial gastrocnemius 
oxidative capacity was assessed at rest from the recovery rate constant (k) of muscle oxygen 
consumption using near-infrared spectroscopy. Step counts and physical activity (average vector 
magnitude units (VMU)/min) were measured over 5-7 days using triaxial accelerometry. 
Untargeted prime and lipid metabolites were measured using liquid chromatography and mass 
spectrometry.  
Results: Muscle k (1.12±0.05 vs. 1.68±0.06min
-1
; P<0.0001; d=1.58) and VMU/min (170±26 vs. 
450±50 VMU/min; P=0.004; d=1.04) were lower in severe COPD (FEV1<50%predicted, 
n=14-16) compared with CON (n=56-60). 129 prime metabolites and 470 lipids with known 
identity were quantified. Using sex as a covariate, lipidomics revealed 24 differentially expressed 
lipids (19 sphingomeylins) in COPD, consequent to a diminished sex difference of 
sphingomeylins in COPD (FDR<0.05; n=44). Total, and some individual, fatty acid 






adjusting for FEV1%predicted, we observed that grouped diacylglycerides (=-0.745; FDR=0.03) 
and triacylglycerides (=-0.811; FDR=0.01) were negatively associated with muscle oxidative 
capacity, but not physical activity, in severe COPD (n=14). Conclusion: Strong negative 
associations relate impaired mitochondrial function to the accumulation of serum aclyglycerides in 
severe COPD. 







Chronic obstructive pulmonary disease (COPD) is associated with airway inflammation, mucus 
hypersecretion, and pulmonary emphysema; each contributing to expiratory flow limitation. 
Unifying symptoms of these heterogeneous phenotypes are dyspnea on exertion and exercise 
intolerance. Exercise intolerance and physical inactivity, not pulmonary obstruction, are the 
strongest predictors of mortality in COPD (1). Although no therapies beyond smoking cessation 
are yet proven to slow disease progression or reduce mortality, pulmonary rehabilitation - a 
multidisciplinary program that includes exercise training - is the most effective treatment in 
releveling symptoms, increasing quality of life, reducing hospitalizations and morbidity in COPD 
patients (2). A primary benefit of pulmonary rehabilitation in COPD is symptom relief and 
increased exercise tolerance, which are mediated by ameliorating skeletal muscle deficits in 
oxidative capacity, thereby delaying the onset of exercise-induced metabolic acidosis and reducing 
the ventilatory demands for a given activity (3). 
 
Several studies of serum metabolomics show metabolic dysregulation in COPD (4-6). Alterations 
in sphingolipid metabolism are common in COPD, suggesting a deficit in lipid metabolism that 
may contribute to smoking-induced lung damage through mitophagy-mediated necroptosis (7). 
Altered mitochondrial β-oxidation, tryptophan metabolism, carnitine/acylcarnitine, reduced 
polyunsaturated fatty acids and high oxidative stress are common findings following cigarette 






is associated with the accumulation of cytotoxic ceramides in lung epithelial cells and reduced 
mitochondrial respiration in skeletal muscle, resulting in insulin resistance and poor glucose 
tolerance (7, 9). 
 
Muscle deconditioning following physical inactivity is associated with a reduced fraction of 
whole-body ATP turnover that is derived from mitochondrial β-oxidation during rest or exercise 
(10). Loss of mitochondrial oxidative capacity in skeletal muscle is, therefore, a primary variable 
implicated in mediating the association between hyperlipidemia and COPD. As both physical 
activity and oxidative capacity are negatively associated with COPD severity (11), this study 
aimed to determine whether lipid metabolite dysregulation in COPD was associated with muscle 
oxidative capacity and/or physical inactivity. We hypothesized that alteration of lipid metabolites 




The population was drawn from the single-center Muscle Health Study, an ancillary study of 
COPDGene (ClinicalsTrials.gov Identifier NCT00608764). A total of 245 current or former 
smokers participated in the Muscle Health Study at The Lundquist Institute between 2013 and 
2016. Inclusion and exclusion criteria were determined by the COPDGene study design (12). 






pack-year smoking history. In addition, those with known or suspected cancer or recent (within 3 
months) hospitalization were excluded. Of the 245 subjects, 107 had serum samples collected for 
metabolomic investigation: 44 with COPD and 63 with normal spirometry acted as controls 
(CON). Participants gave written informed consent to participate as approved by the Institutional 
Review Board at The Lundquist Institute. Data of muscle oxidative capacity and pulmonary 
function from these participants has been previously reported (13). 
 
Additional methodological details are provided in Supplemental Digital Content (see 
Supplemental Digital Content 1, methods for clinical assessments, muscle oxidative capacity, 
prime metabolomics and lipidomics, http://links.lww.com/MSS/C49). 
 
Clinical assessments 
As part of the COPDGene study protocol, clinical data collected included demographics, vital 
signs, medical and smoking history, and current medications. Spirometry was performed 
according to American Thoracic Society guidelines (14). Lung diffusing capacity for carbon 
monoxide (DLCO) was measured after post-bronchodilator spirometry assessment (15). Resting 








Muscle oxidative capacity 
Oxidative capacity of the medial gastrocnemius muscle (k) was assessed using near-infrared 
spectroscopy (NIRS) as described previously (16). Prior work demonstrates, using direct 
measurements in single muscle fibers of varied biochemical phenotypes, that k is directly 
proportional to muscle oxidative capacity (17). The average k of two repeat measurements is 
reported. 
 
Physical activity  
At the end of the visit, participants received a triaxial accelerometer (DynaPort MoveMonitor, 
McRoberts BV, The Hague, the Netherlands) to assess number of steps per day and physical 
activity reported as vector magnitude units (VMU)/min. Activity measurements were considered 
complete if the participant maintained at least 15 hours of wearing time per day for at least 5 of the 
7 days. 
 
Prime metabolomics and lipidomics  
Blood was collected from a peripheral vein using a serum separator tube (8.5 mL, BD Vacutainer) 
and the serum aliquoted (1 mL) and stored at -80C for subsequent analysis. Blood was collected 
typically ~3-4 hours after taking a usual breakfast. Serum samples were shipped to West Coast 








For general statistics, data are presented as mean ± SEM. Baseline subject characteristics, muscle 
oxidative capacity and physical activity were compared by ANOVA and Dunnett’s post hoc test 
using CON as the reference group (continuous variables) or chi
2
-test (categorical variables). 
Routine metabolomics data analysis was performed with MetaboAnlyst 3.0 
(www.metaboanalyst.ca). Differences in metabolite concentrations among groups were assessed 
by analysis of variance (ANOVA) and Fisher’s LSD post hoc test accounting for multiple 
comparisons using false discovery rate (FDR). Association between muscle oxidative capacity or 
physical activity and metabolite concentration was initially assessed using Spearman correlation 
stratified for GOLD class. Subsequently, lipid metabolites were categorized into 17 metabolite 
classes, grouped by their chemical properties, and partial correlation performed with adjustment 
for FEV1 %predicted.  
 
All comparisons were two-sided. Effect sizes are reported as Cohen’s d (d). For metabolite 
analyses, FDR ≤ 0.05 was considered statistically significant. For other analyses, P ≤ 0.05 was 









Participant demographics and clinical characteristics 
The baseline characteristics of the study participants are presented in Table 1. Overall, 55% of the 
107 participants were female, 52% were African American and 48% were non-Hispanic White. 
COPD patients were significantly older than CON, less likely to be current smokers, and had a 
greater representation of non-Hispanic White participants. There were no significant differences 
between the groups in sex, weight, BMI, smoking history, diabetes or hypertension. By definition, 
FEV1/FVC and FEV1 %predicted were lower in COPD than CON. DLCO was significantly lower 
in COPD than CON, but there was no difference in resting SpO2 between the groups (Table 1). 
Additional analyses were made on a sub-group comprised of only severe COPD (FEV1 < 50% 
predicted, n=16). This sub-population is shown separately in Table 1. Except for the degree of 
pulmonary obstruction (by definition) and a lower SpO2 than CON (not clinically significant: 
97.8±2.4 vs 96.1±0.7 %; d = 0.67), severe COPD patients had baseline characteristics that were 
similar to the whole COPD group (Table 1). 
 
Muscle oxidative capacity and physical activity 
Non-invasive measurement of the     2 recovery rate constant, k, was successful in 42 (95%) 
COPD and 56 (89%) CON participants. k was significantly lower in COPD than CON (1.32±0.07 
min
-1
 vs. 1.68±0.06 min
-1
; P < 0.0001; d = 0.81, Figure 1A), and lower still in the COPD patents 
with severe disease (FEV1 <50 %predicted) (1.12 ±0.05 min
-1






1.58) (Figure 1A). Forty-two (95%) COPD and 56 (89%) CON completed at least 5 days of 
triaxial accelerometer monitoring as designed (15 hours per day). Daily number of steps was not 
different between COPD and CON (5254±701 vs. 6188±442 steps/day, P = 0.375; d = 0.23) but 
was lower in severe COPD (3171±568 steps/day; P = 0.010 vs. CON; d = 1.04) (Figure 1B). 
Physical activity was not different between COPD and CON (353±43 vs. 450±50 VMU/min; P = 
0.233; d = 0.30) but was lower in severe COPD (170±26 VMU/min; P = 0.004 vs. CON; d = 1.04) 
(Figure 1C).  
 
Sex differences in serum sphingomyelin were diminished in COPD patients  
Lipidomics analysis using sex as a covariate revealed 24 differentially expressed lipids between all 
COPD and CON (one-way ANOVA) (Figure 2A; FDR < 0.05; d = 0.36-1.31), of which 19 were 
sphingomyelins. Post hoc analysis showed that this effect was driven by a significant difference 
between males and females in the CON group (see Table, Supplemental Digital Content 2, list of 
metabolites and differences, http://links.lww.com/MSS/C50). In CON, sphingomyelin 
concentrations were generally greater in females than males, and 38 sphingomyelin species were 
identified significantly greater in females than in males (Figure 2B; FDR < 0.05; d = 0.58-1.32; 
see Table, Supplemental Digital Content 3, list of sphingomyelins that were significantly different 
between males and females in CON, http://links.lww.com/MSS/C51). Conversely, in COPD, only 
4 sphingomyelins were significantly greater in females than males (Figure 2C; FDR < 0.05; d = 






significantly different between males and females in COPD, http://links.lww.com/MSS/C52). 
These data indicate that the anticipated differences in sphingomyelin concentrations between the 
sexes were diminished in COPD patients.  
 
Fatty acid metabolites were increased in severe COPD patients 
Prime metabolomics and lipidomics analysis identified 129 prime metabolites and 470 lipids with 
known identity in the serum of study participants. Metabolite concentrations were not significantly 
different between COPD and CON. However, several metabolites, predominantly fatty acids, were 
differentially expressed in severe COPD (FEV1 < 50 %predicted; n = 16) compared with CON. In 
lipidomics analysis, total fatty acid concentration was significantly greater in severe COPD than in 
CON (Figure 3A; P < 0.05; d = 1.02). This was predominantly due to 4 fatty acids that were 
significantly greater in severe COPD than in CON (Figure 3B; FDR < 0.05; d = 0.83-0.89). In the 
prime metabolites, the concentrations of 7 fatty acids were significantly greater in severe COPD 
than in CON (Figure 3C; FDR < 0.05; d = 0.59-1.02). 
 
Acylglycerides were negatively associated with muscle oxidative capacity in severe COPD  
Spearman correlation analysis was employed to identify whether metabolite concentrations were 
associated with the     2 recovery rate constant (k) and/or physical activity. All individual 
diacylglyceride (DG) and triacylglyceride (TG) metabolites had negative correlation with muscle 






sex, race and height (18)). There were no significant associations between TG or DG with age, 
BMI, resting systolic or diastolic blood pressure, current smoking status, smoking history, FEV1 
%predicted, incidence of diabetes or hypertension, steps/day or VMU/min. Overall, 7 out of 8 DG 
and 48 out of 102 TG were nominally negatively associated with muscle oxidative capacity in 
severe COPD (Figure 4A, P < 0.05; n = 14). 
 
Next, lipids were grouped into 17 classes based on their characteristics, and partial correlations 
were re-assessed. Following adjustment for FEV1 %predicted and correcting for FDR, we found 
that muscle oxidative capacity was negatively correlated with diacylglyceride concentration ( = 
-0.7447; FDR = 0.03) and triacylglyceride concentration ( = -0.8118; FDR = 0.01) in severe 
COPD patients (n = 14), but not in CON (n = 56). Neither daily steps nor physical activity were 
significantly associated in partial correlation with the concentrations of any metabolite group 
(Figure 4B). Adjustment of the partial correlation analysis using DLCO (a slightly stronger 
correlate of grouped metabolites than FEV1 %predicted), did not change the significant correlation 
between k and DG ( = -0.7544; FDR = 0.02) or TG ( = -0.8116; FDR = 0.01) in the severe 
COPD group (n = 14). Although there was no significant association between BMI and DG or TG, 
we also sought to adjust for BMI due to its potential association with hyperlipidemia. This 
adjustment did not substantively affect the correlation between k and TG ( = -0.7579; FDR = 






remained no association between any lipid metabolite group and any measure of physical activity 
after adjustment for covariates. 
 
DISCUSSION 
In this study, we conducted both prime metabolomic and lipidomics analyses in COPD patients 
and controls, to identify whether serum metabolites were associated with physical activity and/or 
muscle mitochondrial oxidative capacity. We observed: 1) 24 lipids, including 19 sphingomyelins, 
were differentially expressed in COPD with sex as covariant; 2) sex-dependent differences in 
sphingomyelin concentration in controls were diminished in COPD patients; 3) severe COPD 
patients (n = 16) had elevated serum total fatty acids, centered on 8 individual fatty acid 
metabolites; and, 4) serum concentrations of di- and tri-acylglycerides were negatively associated 
with muscle oxidative capacity, and not physical activity, in severe COPD (n = 14). Previous 
metabolomics studies of spirometrically-defined COPD reported dysregulation in several serum 
metabolite classes (4-6). Here we identify that skeletal muscle deconditioning in the form of 
reduced muscle oxidative capacity, common in COPD, may underlie metabolic dysregulation of 
di- and tri-acylglycerides in patients with severe pulmonary obstruction.  
 
Dysregulation of sphingolipid metabolism is common in patients with COPD. In an untargeted 
lipidomic analysis of sputum samples, Telenga et al. (19) demonstrated that sphingolipids, 






those without COPD. Thirteen individual serum lipid metabolites, including one sphingomyelin, 
showed strong negative association with FEV1 and inflammation in sputum. Telenga et al. also 
found that two months of smoking cessation reduced concentration of 26 sphingomyelins in both 
groups (19). Others have demonstrated a significant negative association between sphingomyelin 
metabolites and emphysema from chest CT measurements (5) or COPD exacerbation severity 
(7).  
 
Consistent with studies of healthy subjects (20), our data showed greater serum sphingomyelin 
concentration in females than in males in our control group, which consisted of current or former 
smokers with normal spirometry. We found that this sex difference was diminished in all COPD 
patients, suggesting a sex-dependent alteration of sphingomyelin metabolism in COPD. 
Intracellular ceramide concentration is regulated by sphingolipid metabolism and is implicated in 
cigarette smoking induced mitophagy (7). Sphingolipid metabolism was also associated with 
emphysema progression in sub-phenotyping analysis (21). Whether the diminishing 
sex-differences in circulating sphingomyelin metabolism underlie the more rapid progression of 
COPD observed in women than in men deserves further attention.  
 
We identified that the serum concentration of total fatty acids, and some individual fatty acids, 
were significantly greater in severe COPD (n = 16) than in controls (n = 63). This observation was 






where total free fatty acid concentration was significantly lower in COPD than in healthy controls 
(22). This discrepancy may reflect the disease stage of the subjects in each study; BMI in the 
severe COPD patients in the study of Wada et al. was significantly lower than controls, while there 
was no difference in BMI between groups in our study. 
 
The role of individual circulating fatty acids in the progression of pulmonary, cardiovascular or 
metabolic disease in COPD patients is not well studied. For example, increased dietary intake of 
fatty acids is associated with greater expiratory flow limitation in COPD patients, while dietary 
intake of pentadecylic acid may improve lung function in these patients (23). We found 7 
individual fatty acids in prime analysis and 4 in lipidomics that were greater in severe COPD, with 
3 individual fatty acids recapitulated in both analytic approaches (myristic acid, plamitoleic acid 
and heptadecanoic acid). Myristic acid potentiates palmitic acid-induced lipotoxicity, likely 
through mitochondria-related mechanisms (24). Similar to a previous investigation (25), we found 
that the monounsaturated fatty acid, palmitoleic acid, was greater in severe COPD; which is 
associated with greater high and low density lipoprotein cholesterol (26). On the other hand, lauric 
acid was also increased in severe COPD in our prime analysis, which is implicated in potentially 
beneficial effects on cholesterol, insulin resistance and inflammation. Given the low mitochondrial 
oxidative capacity we found in muscles of severe COPD patients (13), and the known greater odds 
of cardiometabolic disease in severe COPD, the differential effects on COPD or COPD 






Despite variability in the prevalence of hyperlipidemia, subclinical atherosclerosis occurs at a 
greater than expected prevalence in COPD, and is associated with more frequent exacerbations 
(27). Regular physical activity and increased mitochondrial function are associated with lower 
blood lipids and triglycerides, and are protective of metabolic and cardiovascular disease (28). 
Therefore, identifying whether differences in physical activity and/or mitochondrial function 
underlie the observations of lipid metabolite dysregulation in COPD was a major thrust of this 
study. Overall, we did not find significant associations between lipid metabolites and either muscle 
oxidative capacity or physical activity when considering differences between all COPD patients 
and controls. However, there was a significant ceiling effect on these variables, and so we focused 
our analyses on severe disease (FEV1 < 50 %predicted). In severe COPD, there was a strong 
negative association between muscle oxidative capacity and serum di- or tri-acylglycerides ( 
ranged -0.75 to -0.81; n = 14). These associations remained even after adjusting for false discovery 
rate, and FEV1 or DLCO or BMI. It was striking that physical activity (either steps/day or 
VMU/min; n = 16) was not significantly associated any serum lipid metabolite or metabolite group 
investigated. This distinction is important because it implies that mitochondrial metabolic health, 
rather than physical activity per se, may be involved in lipid dysregulation in severe COPD. 
 
Support for this concept is found elsewhere in biology with, for example: a) no reduction in 
mortality in mice selectively bred for high lifelong energy expenditure, whereas rats selectively 






median lifespan (29); b) while high rates of physical activity are known to reduce all-cause 
mortality risk (30), the hazard ratio for mortality in 8,171 male veterans was reduced by ~50% 
when stratifying by exercise capacity compared with stratifying for physical activity (31); c) there 
was no survival benefit of increasing self-reported physical activity in longitudinal study of 1,270 
COPD patients with a median follow-up duration of 17 years (32). On the other hand, it is well 
established that exercise training, as part of a pulmonary rehabilitation program, increases muscle 
oxidative capacity (33), reduces 1-year hospital readmission (odds ratio vs. usual care = 0.44 (95% 
confidence interval 0.21 – 0.91), and potentially reduces 1-year mortality (odd ratio = 0.68 (0.28 – 
1.67)) (2), without an impact on physical activity (34); d) changes in fat free mass and exercise 
capacity (but not physical activity) in COPD are also associated with rapid decline in health status 
(35).  
 
Metabolic syndrome is prevalent in COPD (36). Previous findings identified that an increase in 
circulating triglycerides is a major risk factor for 5-year mortality in COPD patients (37). 
Hypertriglyceridemia and systemic inflammation are independent predictors of elevated 
plasminogen activator inhibitor-1 in COPD, a major inhibitor of fibrinolysis, associated with 
thrombosis, obesity, insulin resistance, dyslipidemia, and premature aging; each prevalent in 
COPD (38). Intracellular accumulation of triglycerides and other fatty acids, promote endoplasmic 
reticulum stress, mitochondrial uncoupling and oxidative stress, which terminates in inflammation 






hypertension, also prevalent in COPD. The association between circulating triglycerides and 
muscle mitochondrial oxidative capacity we identified in severe COPD provides a strong 
justification for the role of increasing physical fitness in reducing cardiovascular and metabolic 
risk in this patient population. Our proposal is that attempts to redress lipid metabolic deficits in 
COPD should not focus on simply diet or activity interventions, but specifically on obtaining the 
health-related benefits associated with increasing muscle (and other tissue) mitochondrial 
oxidative capacity. 
 
There are several limitations to this study. The number of subjects is low, particularly in the severe 
COPD group, which limited the statistical power to detect associations between individual lipid 
metabolites and muscle oxidative capacity or physical activity. Diet and circadian rhythm are 
known to regulate metabolism. Our serum samples were not collected with dietary control or at 
the same circadian time range, both of which could influence postprandial lipid profile and 
contribute to variation in metabolite concentrations. In addition, increased carbohydrate and fatty 
acid intake are associated with worse pulmonary function (23). In attempt to mitigate this 
potential confounder, our findings remained after adjusting for FEV1 %predicted. We were not 
able to include measurements of adiposity or analysis of systemic markers of inflammation, which 
could have contributed to our understanding of lipid dysregulation. The measure of muscle 






and we have demonstrated this method has strong reproducibility in COPD patients (16), while 
others have shown good association (r = 0.61-0.74) with muscle biopsy (40). 
 
In conclusion, we observed that 24 lipids, including 19 sphingomyelins, were increased in COPD 
with sex as covariant, and that sex-dependent differences in sphingomyelin concentration in 
controls were diminished in COPD patients. We also found that severe COPD patients had 
elevated serum total fatty acids, which centered on 8 individual fatty acid metabolites. These 
findings may in part underlie the more rapid progression of COPD observed in women than in 
men and the high prevalence of cardiovascular disease in COPD patients. Lipid dysregulation that 
was negatively associated with muscle oxidative capacity ( ranged -0.75 to -0.81; n = 14), and not 
physical activity (n = 16); a negative association which remained despite adjustment for FEV1 
%predicted, DLCO or BMI. The strong negative association we identified between di- or 
tri-acylglycerides and muscle oxidative capacity, suggests that impaired mitochondrial function 
may play a role in the accumulation of serum aclyglycerides in severe COPD, and provides a 
strong rationale for targeting mitochondrial deficits by exercise training, or other means, to 
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Figure 1. Muscle oxidative capacity and physical activity is reduced in severe COPD patients 
compared with controls (CON). A) Muscle oxygen consumption recovery rate constant (k, 
min
-1
), which is linearly proportional to muscle oxidative capacity (CON n=56; ALL COPD n=42; 
severe COPD n=14). B) Daily steps (CON n=56; ALL COPD n=42; severe COPD n=16). C) 
Average daily VMU/min (CON n=56; ALL COPD n=42; severe COPD n=16). 
 
Figure 2. The sex difference of serum sphingomyelin concentration was diminished in 
COPD patients compared with controls (CON). (A) ANOVA of lipidomics of COPD patients 
(n=44) and CON (n=63) with sex as a covariant. Filled red circles indicate metabolites with 
significant difference among groups. (B) Comparison of sphingomyelin (SM) concentration 
between male and female CON subjects (n=63). (C) Comparison of sphingomyelin (SM) 
concentration between male and female COPD patients (n=44). Filled pink circles indicate 
metabolites with significant difference between the sexes. Data were corrected for false discovery 
rate (FDR).  
 
Figure 3. Fatty acids were increased in severe COPD patients compared with controls. Lipid 
metabolites in severe COPD patients (FEV1 < 50% predicted, open symbols/open bars) compared 
with CON (filled symbols/filled bars). (A) Total fatty acids were significantly greater in severe 






identified as significantly greater in severe COPD patients in lipidomics analysis. (C) Seven fatty 
acids were identified as significantly greater in severe COPD patients in prime metabolite analysis. 
Data were corrected for false discovery rate (FDR): * FDR<0.05; ** FDR<0.01; *** FDR< 0.005; 
**** FDR<0.001; CON n=63; severe COPD n=16.  
 
Figure 4. Diacylglyceride (DG) and triacylglyceride (TG) classes of lipid metabolites were 
correlated with muscle oxidative capacity in severe COPD. (A) Spearman correlation analysis 
of 470 individual lipid metabolites with muscle oxidative capacity in severe COPD. Individual 
metabolites were placed into classes based on their characteristics, shown in panel B. (B) Partial 
correlation of grouped lipid metabolites with muscle oxidative capacity, daily steps and physical 
activity (VMU/min). Data were adjusted for FEV1 % predicated and corrected for FDR. 
Statistically significant associations were identified for DG and TG classes (panel B). DG and TG 
regions within the individual metabolite data are highlighted in panel A by horizontal dash. * 
FDR<0.05. Severe COPD n=14-16. 
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Table 1. Participant characteristics. 













Number of Subjects n 63 44 16 - - 
GOLD 1/2/3/4 n 0 / 0 / 0 / 0 14 / 14 / 9 / 7 9 / 7 - - 
Age years 61.2 ± 1.3 65.6 ± 1.4 66.6 ± 1.6 0.039 0.086 
Sex, M / F n 29 / 34 21 / 23 6 / 10 0.981 0.786 
Race, NHW / AA n 21 / 42 30 / 14 13 / 3 <0.0001 <0.001 
Weight kg 85.3 ± 2.7 79.2 ± 2.6 78.1 ± 4.7 0.209 0.330 
BMI kg/m
2
 29.8 ± 0.9 28.2 ± 0.9 29.2 ± 1.8 0.405 0.941 
Smoking history pack-years 39.2 ± 2. 6 46.5 ± 3.6 47.0 ± 6.4 0.187 0.372 
Smoking duration years 35.6 ± 1.3 37.2 ± 1.5 35.4 ± 2.7 0.656 0.997 
Current smoker n (%) 34 (54) 13 (30) 3 (13) 0.020 0.018 
FEV1/FVC % 79.6 ± 0.7 52.5 ± 2.4 35.8 ± 3.3 <0.0001 <0.0001 










Diabetes n (%) 13 (21) 4 (9) 1 (6) 0.181 0.265 
Hypertension n (%) 36 (57) 21 (48) 8 (50) 0.557 0.844 
SpO2 % 97.8 ± 2.4 97.3 ± 2.0 96.1 ± 0.7 0.421 0.015 
GOLD, global initiative for obstructive lung disease spirometric classification (1, Mild; 2, 
Moderate; 3, Severe; 4, Very-severe); NHW, non-Hispanic White; AA, African American; BMI, 
body mass index; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; DLCO, 
diffusing capacity for carbon monoxide; SpO2, oxyhemoglobin saturation by pulse oximetry. 
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As part of the COPDGene study protocol, clinical data collected included demographics, vital 
signs, medical and smoking history, and current medications.  
 
Spirometry was performed according to American Thoracic Society guidelines (21) usin  a dua  
 ea  Dopp er u trasound- ased spiro eter (Eas  ne  ro   dd edica     rich  S itzer and). 
Participants inhaled two puffs of metered dose albuterol sulfate (ProAir HFA, Teva Respiratory, 
Horsham, PA, USA) 15 minutes before spirometric testing. Forced expiratory volume in 1 second 
(FEV1) and forced vital capacity (FVC) were measured from the greatest FEV1 and FVC from up 








Lung diffusing capacity for carbon monoxide (DLCO) was measured after the post-bronchodilator 
spirometry assessment (EasyOne Pro DLCO   dd edica     rich  S itzer and) (22). DLCO 
measurement was made following an exhalation to residual volume, followed by a rapid 
inspiration to total lung capacity and breath hold for 8-12 seconds. The maneuver ended with a 
complete exhalation to residual volume and resumption of normal breathing. This procedure was 
performed at least 2 and no more than 5 times. The test was accepted when 2 maneuvers were 
within 3 mL.min
-1
.mmHg or within 10% of the greatest value.  
 
Resting arterial oxygen saturation was measured using pulse oximetry (SpO2; Rad-5 Pulse 
Oximeter MasimoSET®, Masimo Co., Irvine, CA). 
 
Muscle oxidative capacity 
Oxidative capacity of the medial gastrocnemius muscle was assessed using near-infrared 
spectroscopy (NIRS) (23, 24). Briefly, a wireless, portable, continuous-wave, spatially-resolved 
NIRS probe (PortaMon, Artinis, The Netherlands) was wrapped in plastic film and secured with an 
elastic bandage to the belly of the medial gastrocnemius to measure relative change in oxygenated 
and deoxygenated myoglobin + hemoglobin. From these, tissue saturation index (TSI, %), and the 
relative change in total tissue myoglobin + hemoglobin was calculated. A 13 x 85 cm 
rapid-inflation pressure-cuff (SC12D, Hokanson, USA) was placed proximally on the thigh of the 






familiarized with rapid cuff inflation procedures. During familiarization the pressure required for 
arterial occlusion was identified (range 230–300 mmHg). Participants lay at rest for ~3 min to 
determine resting muscle TSI and SpO2 at the fingertip (Rad-5 Pulse Oximeter MasimoSET®, 
Masimo Co., Irvine, CA). Participants then performed 10–12 cycles of ~1 Hz plantar-flexion 
muscle contractions, followed immediately by arterial occlusion until a stable minimum TSI was 
reached, or for 5 min (whichever came first). This was used to establish an individualized 
physiologic range (maximum and minimum) of muscle TSI(23) After at least 3 min recovery, 
participants performed ~10-15 s plantar-flexion muscle contractions to increase muscle oxygen 
upta e (    2) and desaturate the muscle to ~50% of physiologic range(23) ; this was followed 
immediately by a series of intermittent arterial occlusions (5 occlusions for 5 s; 10 for 10 s; each 
separated by 5–20 s recovery; total duration ~6 min). This last ~6 min phase was repeated after ~2 
min rest. For each brief arterial occlusion, the rate of decline in TSI (%.s
-1
) was calculated to 
determine relative    2.  he    2 recovery rate constant (k, min
−1
) as easured    non- inear 
 east-s uares re ression of the     2 exponential recovery (OriginPro v8.6, OriginLab Co., 
Northampton, USA) (23). k is directly proportional to muscle oxidative capacity (25). The average 
k of two repeats is reported.  
 
Prime metabolomics and lipidomics  
Post-prandial blood was collected from a peripheral vein using a serum separator tube (8.5 mL, BD 






Serum samples were shipped to West Coast Metabolomics Center at the University of California, 
Davis on dry ice for metabolomics analysis. For untargeted assessment of primary metabolites, gas 
chromatography time-of-flight mass spectrometry (GC-TOF MS) method was used as described 
(26). Briefly, 30 µL serum samples and internal standards were extracted and derivatized by 
silylation/methyloximation. Metabolites were separated using an Agilent 6809 gas chromatograph 
(Agilent Technologies, Santa Clara, CA, USA). Mass spectrometry was performed with a Leco 
Pegasus IV time of flight mass spectrometer. Peak heights of quantifier ions for each metabolite 
were determined by comparing with internal standards. For untargeted lipidomics, serum samples 
were extracted in methyl tert-butyl ether with the addition of internal standards, followed by 
ultra-high pressure liquid chromatography on a Waters CSH column, interfaced to a quadrupole 
time-of-flight mass spectrometer (high resolution, accurate mass), with a 15-minute total run time. 
Peak areas of lipid species within the range of the calibration curves were analyzed by comparing 
the individual peak areas with those of corresponding internal standards for determining the final 
concentration of each metabolite. Data were collected in both positive and negative ion mode and 
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Supplementary Table SDC 1. Lipid metabolites that showed sex differences in one-way ANOVA. Nineteen out of 24 metabolites that 
were different between the sexes were sphingomyelins. 
Metabolite F value P value FDR Fisher’s LSD 
SM d322 A 16.224 1.04E-08 4.39E-06 COPD-F vs. COPD-M; COPD-F vs. CON-M; CON-F vs. COPD-M; CON-F vs.CON-M 
SM d322 B 13.068 2.68E-07 5.66E-05 COPD-F vs. COPD-M; COPD-F vs.CON-M; CON-F vs. COPD-M; CON-F vs.CON-M 
SM d301A 10.025 7.45E-06 0.001048 COPD-F vs. COPD-M; COPD-F vs.CON-F; COPD-F vs.CON-M; Con-F vs.CON-M 
SM d371 A 7.7381 0.000104 0.010925 COPD-F vs. COPD-M; COPD-F vs.CON-M; CON-F vs.CON-M 
SM d412 A  7.2925 0.000175 0.011198 COPD-F vs.CON-M; COPD-M vs.CON-M; CON-F vs.CON-M 
SM d402 A 7.2063 0.000194 0.011198 COPD-F vs. COPD-M; COPD-F vs.CON-M; CON-F vs.CON-M 
SM d321 A 7.1344 0.000212 0.011198 COPD-Fvs. COPD-M; COPD-Fvs.CON-M; CON-F vs.CON-M 





SM d403 7.0219 0.000242 0.011338 COPD-F vs.CON-M; CON-F vs.COPD-M; CON-F vs.CON-M 
SM d363 A 6.6337 0.000385 0.015247 COPD-F vs.CON-M; COPD-M vs.CON-M; CON-F vs.CON-M 
SM d321 B 6.5523 0.000424 0.015247 COPD-F vs. COPD-M; COPD-F vs.CON-M; CON-F vs.CON-M 
SM d342A 6.5343 0.000434 0.015247 COPD-F vs.CON-M; COPD-F vs.CON-M; CON-F vs.CON-M 
SM d423 A 5.9594 0.000869 0.026405 COPD-F vs.CON-M; CON-F vs.CON-M 
SM d342B 5.9524 0.000876 0.026405 COPD-F vs.CON-M; CON-F vs.CON-M 
SM d371 B 5.7273 0.001152 0.032411 COPD-F vs.CON-M; CON-F vs. COPD-M; CON-F vs.CON-M 
PC 343 A 5.6496 0.001267 0.033407 COPD-F vs.CON-M; CON-F vs.CON-M 
SM d392 B 5.5296 0.001467 0.033769 COPD-F vs. COPD-M; COPD-F vs.CON-M; CON-F vs. COPD-M; CON-F vs.CON-M 
PC 352 A 5.5039 0.001514 0.033769 COPD-F vs.CON-M; CON-F vs.CON-M 
SM d363 B 5.4571 0.001603 0.033769 COPD-F vs.CON-M; CON-F vs.CON-M 
SM d391 5.4289 0.001659 0.033769 COPD-F vs. COPD-M; COPD-F vs.CON-M; CON-F vs.CON-M 
Ceramide d321 5.3837 0.001754 0.033769 COPD-F vs.CON-F; COPD-F vs.CON-M; COPD-M vs.CON-M; CON-F vs.CON-M 





SM d423 B 5.2575 0.002048 0.037568 COPD-F vs.CON-M; CON-F vs. COPD-M; CON-F vs.CON-M 
FA 161  5.2165 0.002153 0.037862 COPD-F vs. COPD-M; COPD-F vs.CON-F; COPD-F vs.CON-M 
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Supplementary Table SDC 2. Sphingomyelin (SM) metabolite concentrations that were 
significantly different between males and females in the smoker control group. 
 T value P value FDR 
SM d322 A 5.0406 4.42E-06 0.000207 
SM d322 B 4.9329 6.57E-06 0.000207 
SM d403 4.2554 7.30E-05 0.001534 
SM d423 A  4.0718 0.000137 0.002151 
SM d412 A 3.9271 0.000221 0.00243 
SM d363 A  3.9139 0.000231 0.00243 
SM d402 A 3.8024 0.000334 0.002496 
SM d371 B 3.7873 0.000351 0.002496 
SM d412 B 3.782 0.000357 0.002496 
SM d363 B  3.7262 0.000427 0.002692 
SM d342 A  3.6856 0.000487 0.002788 






SM d301 A 3.5964 0.000647 0.003135 
SM d342 B 3.5445 0.000762 0.003428 
SM d321 A  3.3925 0.001221 0.005128 
SM d362 A 3.3449 0.001412 0.005415 
SM d371 A 3.3336 0.001461 0.005415 
SM d321 B 3.2448 0.00191 0.006683 
SM d412 C 3.1006 0.002922 0.009211 
SM d362 B 3.0916 0.003 0.009211 
SM d320 A 3.0836 0.00307 0.009211 
SM d382 A  2.9913 0.004004 0.011466 
SM d392 B 2.971 0.004242 0.01162 
SM d301 B 2.9399 0.004633 0.011918 
SM d391 2.9325 0.004729 0.011918 
SM d331 A 2.8927 0.005288 0.012814 
SM d382 B 2.7557 0.007712 0.017995 
SM d340 A 2.7387 0.008075 0.018169 
SM d331 B 2.6503 0.01023 0.022224 
SM d402 B 2.5422 0.013571 0.028499 






SM d432 A 2.4614 0.016685 0.032729 
SM d402 A 2.4506 0.017144 0.032729 
SM d422 A 2.4276 0.018164 0.033641 
SM d432 B 2.4163 0.018689 0.033641 
SM d361 B 2.3764 0.020638 0.036116 
SM d340 B 2.3105 0.024257 0.041302 
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Supplementary Table SDC 3. Sphingomyelin (SM) metabolite concentrations that were 
significantly different between males and females in the COPD group.  
 T value P value FDR 
SM d322 A 4.450 0.00006 0.00391 
SM d301 A 3.769 0.00051 0.01593 
SM d322 B 3.618 0.00079 0.01663 
SM d301 B 3.264 0.00219 0.03445 
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